Targeted Nanoparticle Reprogramming of Tumor-Associated Macrophages
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies targeting immunosuppressive tumor-associated macrophages (TAMs) fail to effectively reprogram them into tumor-killing macrophages, leading to tumor growth and metastasis, and often induce systemic side effects due to non-specific macrophage suppression.
Innovation Solution
Delivering nucleotides encoding activation regulators, such as interferon-regulatory factor 5 (IRF5) and kinase IKKβ, via targeted nanoparticles to reprogram TAMs into tumoricidal macrophages, utilizing a particle size of <130 nm and a TAM-targeting ligand to ensure selective uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapies target immunosuppressive TAMs to kill them, then immunosuppression in tumor microenvironment is alleviated, but TAMs are simply replaced with newly-arriving macrophages and systemic side effects occur
Solution Approach 1:
The patent applies local quality by designing nanoparticles with tumor-specific targeting ligands (anti-CD64 antibodies, mannose residues) that enable selective accumulation and activation only within the tumor microenvironment. This localized approach transforms TAMs into tumoricidal macrophages (M1 phenotype) specifically at the tumor site while leaving systemic macrophages unaffected, thereby achieving therapeutic effectiveness without systemic immunosuppression side effects
Solution Approach 2:
The patent uses nanoparticles as intermediaries to deliver activation regulators (transcription factors IRF5, NF-κB, and kinase IKKβ) directly to TAMs in the tumor microenvironment. These nanoparticles act as carriers that protect the regulators from degradation, enable targeted delivery via ESR1 receptor binding, and facilitate controlled release within tumor-associated macrophages, thereby achieving precise local reprogramming without systemic exposure
2Reliability
If small molecule drugs and antibodies are used to suppress TAMs, then some therapeutic success is achieved, but all macrophages in the body are suppressed inducing dangerous side effects
Solution Approach 1:
The patent employs local quality by equipping nanoparticles with tumor-specific targeting moieties (anti-CD64 antibodies targeting Fcγ receptors, mannose residues binding to mannose receptors on TAMs) that ensure selective recognition and uptake by tumor-associated macrophages. This targeted delivery mechanism achieves high selectivity, suppressing only TAMs in the tumor microenvironment while preserving the function of circulating and tissue-resident macrophages throughout the body
Solution Approach 2:
The patent applies segmentation by dividing the therapeutic approach into distinct functional modules: (1) targeting module with anti-CD64 antibodies and mannose residues for TAM-specific recognition, (2) delivery module using nanoparticle carriers for protected transport, and (3) activation module containing transcription factors (IRF5, NF-κB) and kinase (IKKβ) for M1 polarization. This segmented design enables precise spatial and functional control, achieving therapeutic success with high selectivity
3Reliability
If nucleotides encoding activation regulators are delivered via nanoparticles, then TAMs are reprogrammed into tumoricidal macrophages, but particle size and targeting specificity must be optimized
Solution Approach 1:
The patent applies parameter changes by systematically optimizing nanoparticle physical-chemical properties: size (50-200 nm diameter for optimal ESR1 receptor binding and tumor penetration), surface charge (neutral to slightly negative to reduce non-specific binding), and composition (lipid-based or polymeric matrices for controlled nucleotide release). These parameter adjustments maximize reprogramming efficiency while maintaining manageable design complexity
Solution Approach 2:
The patent achieves universality by designing a multi-functional nanoparticle platform that simultaneously performs: (1) targeting via anti-CD64 antibodies and mannose residues, (2) protection of nucleotide cargo from nucleases, (3) cell membrane penetration through endocytosis, (4) controlled release of transcription factors and kinase, and (5) induction of M1 macrophage polarization. This universal platform can be adapted to deliver different activation regulators for various tumor types without requiring complete redesign
Data Source
AI summary
Systems and methods to modulate the activation state of immune cells in vivo are described. The systems and methods can be used to transform immunosuppressive macrophages that support cancer growth and metastasis into highly activated tumoricidal macrophages.